Echinocandins
Also referenced as: Caspofungin, Micafungin, Anidulafungin, Rezafungin
A family of cyclic lipopeptide antifungal medicines, not one peptide.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved family members include caspofungin, micafungin, anidulafungin and rezafungin. Indications differ; rezafungin treats selected adult candidemia or invasive candidiasis with limited alternatives.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A family of cyclic lipopeptide antifungal medicines, not one peptide.
FDA-approved family members include caspofungin, micafungin, anidulafungin and rezafungin. Indications differ; rezafungin treats selected adult candidemia or invasive candidiasis with limited alternatives.
Members have different labels; antifungal action is not antibacterial action or general immune enhancement.
Why It's Being Studied
- Invasive fungal infections
- Candida
- Fungal cell-wall synthesis
Mechanism of Action
They inhibit fungal beta-(1,3)-D-glucan synthesis, impairing fungal cell-wall integrity.
They inhibit fungal beta-(1,3)-D-glucan synthesis, impairing fungal cell-wall integrity. Members have different labels; antifungal action is not antibacterial action or general immune enhancement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Invasive fungal infections
- Candida
- Fungal cell-wall synthesis
- Intravenous approved medicines
Evidence Summary
Human antifungal trials support product-specific candidiasis and other labeled infection indications.
Higher tiers carry more weight. Filled tiers have evidence for Echinocandins; tap to read it.
- Human antifungal trials support product-specific candidiasis and other labeled infection indications.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Human antifungal trials support product-specific candidiasis and other labeled infection indications.
Reported Adverse Events in Research
- Hypersensitivity, infusion reactions, liver abnormalities, resistance and limited penetration at some sites matter.
Limitations of Current Evidence
- Members have different labels; antifungal action is not antibacterial action or general immune enhancement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Echinocandins | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous approved medicines | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Echinocandins — regulatory document